Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III SYS6010 + SG001 ± chemotherapy in advanced esophageal squamous cell carcinoma
ChiCTR2500112440Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of CPO301, PBI-1308, camrelizumab and tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (13 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Incidence of Dose-Limiting Toxicities (DLTs), Adverse Events (AEs) and 5 more. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
CPO301PBI-1308camrelizumabtislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500112440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112440.